Neoleukin Therapeutics to Host Investor R&D Showcase Highlighting De Novo Protein Therapeutics
15 juin 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, June 15, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Appointment of Erin Lavelle to Board of Directors
01 juin 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, June 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at Jefferies Virtual Healthcare Conference
27 mai 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, May 27, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Virtual Annual Meeting II
15 mai 2020 07h00 HE
|
Neoleukin Therapeutics, Inc.
-Preclinical Data on Lead Immunotherapy Candidate NL-201 Including Immunogencity Results in Non-Human Primates--Novel Conditional Activation Platform Enabled by De Novo Protein Technology--Preclinical...
Neoleukin Therapeutics to Present at Virtual BofA Securities 2020 Health Care Conference
07 mai 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
06 mai 2020 16h01 HE
|
Neoleukin Therapeutics, Inc.
- IND submission for NL-201 anticipated by end of 2020 - - Three abstracts to be presented at AACR-II - SEATTLE, May 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”)...
Neoleukin Therapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held May 5, 2020
16 avr. 2020 16h05 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, April 16, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities
09 avr. 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, April 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Year End Financial Results
12 mars 2020 16h01 HE
|
Neoleukin Therapeutics, Inc.
- NL-201 IND Submission Expected by End of 2020 - - Company to host Conference Call Today, March 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern - SEATTLE, March 12, 2020 (GLOBE NEWSWIRE) --...
Neoleukin Therapeutics to Host 2019 Financial Results Conference Call and Webcast on March 12, 2020
05 mars 2020 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, March 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...